Indications and Usage

Thyroid Tablets, USP are indicated for: 

  • Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis) 

  • TSH suppression in the management of certain goiters and in thyroid cancer 

Contraindications: 

  • Uncorrected adrenal cortical insufficiency 

  • Untreated thyrotoxicosis 

  • Known hypersensitivity to thyroid hormone preparations or excipients 

Important Risk Information

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

  • Thyroid hormones, alone or in combination, should not be used for weight loss or obesity treatment. 

  • In euthyroid patients, doses within normal hormonal requirements are ineffective for weight reduction. 

  • Larger doses may produce serious or life‑threatening toxicity, particularly when used with sympathomimetic amines. 

Warnings and Precautions

Cardiovascular Risk

  • Use with extreme caution in:  

    • Patients with coronary artery disease or angina 

    • Elderly patients 

  • Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:  

    • Angina 

    • Arrhythmias 

    • Myocardial infarction 

Risk of Over‑Replacement (Hyperthyroidism) 

  • Excess dosing may result in symptoms of hyperthyroidism, including:  

    • Palpitations 

    • Tachycardia 

    • Nervousness 

    • Heat intolerance 

  • Liothyronine (T3) content may produce more rapid and pronounced effects 

Endocrine Effects

  • May worsen:  

    • Diabetes mellitus (increased insulin/oral hypoglycemic requirements) 

    • Adrenal insufficiency (must be corrected prior to therapy) 

  • Requires careful monitoring and dose adjustment 

Anticoagulant Sensitivity 

  • Thyroid hormones may increase response to oral anticoagulants 

  • Monitor prothrombin time/INR and adjust anticoagulant dose as needed

Special Populations 

  • Pediatric patients: Excess dosing may cause craniosynostosis 

  • Pregnancy: Continue therapy; dose adjustments may be required 

  • Lactation: Use with caution 

Adverse Reactions 

  • Adverse reactions are generally due to overdosage and resemble hyperthyroidism:  

    • Palpitations 

    • Tachycardia 

    • Arrhythmias 

    • Nervousness 

    • Insomnia 

    • Tremor 

    • Heat intolerance 

  • Other reactions are rare when properly dosed 

Drug Interactions 

  • Decreased absorption:  

    • Cholestyramine (separate dosing by 4–5 hours) 

  • Increased anticoagulant effects 

  • Altered glycemic control with insulin or oral hypoglycemics 

  • Estrogens/oral contraceptives:  

    • May increase thyroid hormone requirements 

Dosage and Administration  

  • Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3) 

  • Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease 

  • Administer orally; consistency in administration is important 

This is the most important safety information you should know about AMERITHROID®. For more information, talk with your doctor. 

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. 

Manufactured for: Oliva Therapeutics, LLC

Ridgewood, NJ 07450 

Rev 05/2026 

Oliva Therapeutics is proud to introduce amerithroid—a naturally derived, T3/T4 treatment for hypothyroidism

Oliva is backed by the legacy of Jerome Stevens Pharmaceuticals (JSP), the family-owned and operated U.S. manufacturer of Unithroid®, the first FDA approved levothyroxine sodium tablets product

Oliva is backed by the legacy of Jerome Stevens Pharmaceuticals (JSP), the family-owned and operated U.S. manufacturer of Unithroid®, the first FDA approved levothyroxine sodium tablets product

Oliva is backed by the legacy of Jerome Stevens Pharmaceuticals (JSP), the family-owned and operated U.S. manufacturer of Unithroid®, the first FDA approved levothyroxine sodium tablets product

amerithroid is 100% U.S.-sourced and manufactured; made in America by Jerome Stevens Pharmaceuticals (JSP), distributed by Oliva Therapeutics

Arriving: June 2026

Arriving: June 2026

Bookmark this page to make it easy to check back for more information.

Bookmark this page to make it easy to check back for more information.

Amerithroid (Thyroid Tablets, USP)
Strength (mg)
Strength (Grain)
Oliva NDC Number

15 mg

1/4 grain

82685-341-01

30 mg

1/2 grain

82685-342-01

60 mg

1 grain

82685-343-01

90 mg

1 1/2 grain

82685-344-01

120 mg

2 grain

82685-345-01

180 mg

3 grain

82685-346-01

240 mg

4 grain

82685-347-01

300 mg

5 grain

82685-348-01

Oliva Therapeutics is a new kind of thyroid company—built with purpose, guided by experience, and focused on a single mission: restoring confidence in thyroid care.

Backed by the legacy of Jerome Stevens Pharmaceuticals, (JSP), Oliva is committed to elevating the standard of thyroid care while meeting the real-world needs of both patients and providers.

jerome stevens pharmaceuticals, inc. logo

Note that DTE products, including amerithroid™, have not been reviewed by the FDA for safety or efficacy.